This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The hypothesis of AIM-HIGH is that combination anti-dyslipidemic therapy (extended-release niacin plus simvastatin) will be superior to statin monotherapy alone (simvastatin) when used as secondary prevention in reducing long-term clinical events in patients with documented vascular disease and atherogenic dyslipidemia. Based on these selection criteria, the vast majority of these patients are anticipated to satisfy current NCEP ATP III criteria for a diagnosis of metabolic syndrome. The primary objective of the study is to assess, during a 3-5 year follow-up, the comparative efficacy and safety of statin monotherapy (simvastatin) versus combination therapy (niacin extended-release plus simvastatin), at comparable levels of on-treatment LDL-C, in reducing the risk for clinical events in vascular disease patients with atherogenic dyslipidemia.
Showing the most recent 10 out of 381 publications